H.C. Wainwright has reduced its price target for Rhythm Pharmaceuticals (RYTM) to $110 from $125, reflecting a more conservative view of the company's near-term growth trajectory. The adjustment comes without new financial data or operational updates.
- H.C. Wainwright lowered RYTM's price target to $110 from $125.
- The adjustment reflects a more cautious outlook on market expansion for setmelanotide.
- No new clinical or financial data was disclosed in connection with the revision.
- RYTM stock traded near $105 following the announcement.
- The change is one of several recent analyst updates but not indicative of broader sector trends.
- Analyst maintains 'Buy' rating, signaling confidence in long-term fundamentals.
H.C. Wainwright has revised its price target for Rhythm Pharmaceuticals (RYTM) downward to $110, down from $125, citing a reassessment of the company’s growth potential in the rare disease therapeutic space. The change reflects a more cautious stance on the commercialization timeline and market penetration of Rhythm’s lead candidate, setmelanotide, particularly in broader patient populations beyond those with POMC, PCSK1, or LEPR deficiency-related obesity. The price target revision is based on internal modeling and market dynamics, including competitive pressures from emerging therapies in the metabolic and rare genetic disorder segments. Analysts noted that while Rhythm continues to demonstrate clinical efficacy in its targeted patient groups, the overall addressable market remains limited, and regulatory and reimbursement hurdles could delay broader adoption. RYTM’s stock has seen volatility in recent months, with trading around $105 at the time of the update. The $15 reduction in the price target implies a potential 14% downside from current levels, though the firm maintains a 'Buy' rating, signaling continued confidence in long-term value creation. The move affects investor sentiment among healthcare-focused funds and biotech investors tracking Rhythm’s pipeline. While the change is limited to one analyst firm, it may prompt broader reassessment of valuation metrics within the rare disease therapy sector, especially for companies with narrow patient populations and high R&D costs.